AD-RIDDLE

The AD-RIDDLE project gathers 24 experts from the public and private sectors from across Europe in order to transform the detection, diagnosis, and treatment of Alzheimer's disease. This interdisciplinary initiative is designed to provide healthcare providers with a set of innovative tools to improve disease identification and management.

Throughout five years, the project will develop a modular platform, which will include:

• A digital portal for community participation.
• Advanced detection tools to increase precision in risk progress and early diagnosis.
• Support in clinical decision-making for healthcare providers.
• Customised therapies, tailored to the patients’ individual needs.

With AD-RIDDLE, we are moving toward a more customised and effective approach in the fight against Alzheimer's, combining technology, science, and medicine to improve the quality of life of the affected individuals.

Principal Investigator: Marc Suárez-Calvet

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No. 101132933.The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe, with Davos Alzheimer’s Collaborative, Combinostics OY., Cambridge Cognition Ltd., C2N Diagnostics LLC, and neotiv GmbH.